Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.

Author: DressmanMarlene A, LegerDamien, OgrizekPascale, PerryChristina A, Quera-SalvaMaria-Antonia, VecchieriniMarie-Françoise

Paper Details 
Original Abstract of the Article :
Tasimelteon, a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA). Tasimelteon is a potent and specific melatonin (MT1 and MT2) receptor agonist with 2 - 4 times greater affin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1517/14740338.2015.1093112

データ提供:米国国立医学図書館(NLM)

Tasimelteon: A Safe and Effective Treatment for Non-24-Hour Sleep-Wake Disorder

This study examines the safety profile of tasimelteon, a novel medication specifically developed to treat Non-24-hour Sleep-Wake Disorder (Non-24), a circadian rhythm disorder characterized by a disrupted sleep-wake cycle. The researchers analyzed pooled safety data from six clinical trials to assess the safety and tolerability of tasimelteon.

The analysis revealed a favorable safety profile for tasimelteon, with no serious adverse events reported. The medication was found to be well-tolerated, and the most common adverse effects were mild and transient. This study provides reassurance about the safety of tasimelteon for the treatment of Non-24.

The study highlights the importance of thorough safety assessments in the development of new medications.

Tasimelteon: A Light in the Darkness of Sleep Disorders

The study provides reassuring evidence about the safety of tasimelteon, offering hope for individuals suffering from Non-24. The medication appears to be well-tolerated with a favorable safety profile, suggesting a promising treatment option for this challenging sleep disorder.

Restoring Balance in the Desert of Sleep: What This Means for You

If you are struggling with Non-24, it's important to consult with your doctor about available treatment options. Tasimelteon, with its favorable safety profile, may offer a potential solution for restoring a more balanced sleep-wake cycle. Remember, a good night's sleep is essential for overall health and well-being. This research offers a glimmer of hope for individuals seeking to reclaim their sleep and improve their quality of life.

Dr.Camel's Conclusion

This study offers a refreshing oasis in the desert of sleep disorders. Tasimelteon, with its favorable safety profile, appears to be a promising solution for Non-24, a condition that can significantly disrupt daily life. It's a reminder that even in the face of challenging sleep disturbances, there are avenues for finding relief and restoring balance. By staying informed and consulting with healthcare professionals, we can navigate the sands of sleep disorders and reclaim a more restful and fulfilling life.

Date :
  1. Date Completed 2016-06-08
  2. Date Revised 2015-11-17
Further Info :

Pubmed ID

26393492

DOI: Digital Object Identifier

10.1517/14740338.2015.1093112

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.